Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2011

Open Access 01-03-2011

Pathogenesis of HIV in the Central Nervous System

Authors: Victor Valcour, Pasiri Sithinamsuwan, Scott Letendre, Beau Ances

Published in: Current HIV/AIDS Reports | Issue 1/2011

Login to get access

Abstract

HIV can infect the brain and impair central nervous system (CNS) function. Combination antiretroviral therapy (cART) has not eradicated CNS complications. HIV-associated neurocognitive disorders (HAND) remain common despite cART, although attenuated in severity. This may result from a combination of factors including inadequate treatment of HIV reservoirs such as circulating monocytes and glia, decreased effectiveness of cART in CNS, concurrent illnesses, stimulant use, and factors associated with prescribed drugs, including antiretrovirals. This review highlights recent investigations of HIV-related CNS injury with emphasis on cART-era neuropathological mechanisms in the context of both US and international settings.
Literature
1.
• Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 2008;16(2):94–8. This article reports the preliminary findings of the CHARTER study in the US. This study evaluated over 1000 subjects and estimated the prevalence of HAND in the current era. It is striking that the proportion of subjects with some level of impairment has not changed since prior to cART, when considered by disease stage. PubMed
2.
Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, et al. Neurologic disease burden in treated HIV/AIDS predicts survival. A population-based study. Neurology. 2010.
3.
Sacktor N, Nakasujja N, Robertson K, Clifford DB. HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of clade diversity. Nat Clin Pract Neurol. 2007;3(8):436–43.CrossRefPubMed
4.
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99.CrossRefPubMed
5.
6.
Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42–52.CrossRefPubMed
7.
Hoare J, Fouche JP, Spottiswoode B, Joska JA, Schoeman R, Stein DJ, et al. White matter correlates of apathy in HIV-positive subjects: a diffusion tensor imaging study. J Neuropsychiatry Clin Neurosci. 2010;22(3):313–20.PubMed
8.
Warriner EM, Rourke SB, Rourke BP, Rubenstein S, Millikin C, Buchanan L, et al. Immune activation and neuropsychiatric symptoms in HIV infection. J Neuropsychiatry Clin Neurosci. 2010;22(3):321–8.PubMed
9.
Valcour V, Watters MR, Williams AE, Sacktor N, McMurtray A, Shikuma C. Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol. 2008:1–6.
10.
Morgan EE, Woods SP, Scott JC, Childers M, Beck JM, Ellis RJ, et al. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol. 2008;30(1):83–90.CrossRefPubMed
11.
• Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, et al. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog. 2010;6(4):e1000842. This study using the macaque model of SIV encephalitis demonstrates migration of monocytes from bone marrow to brain with correlations to degree of encephalitis. CrossRefPubMed
12.
Liu Y, Tang XP, McArthur JC, Scott J, Gartner S. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol. 2000;6 Suppl 1:S70–81.PubMed
13.
Valcour VG, Shiramizu BT, Shikuma CM. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol. 2010;87(4):621–6.CrossRefPubMed
14.
Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol. 2009:1–11.
15.
Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol. 2005;64(6):529–36.PubMed
16.
Kumar AM, Borodowsky I, Fernandez B, Gonzalez L, Kumar M. Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol. 2007;13(3):210–24.CrossRefPubMed
17.
Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol. 2009;66(2):253–8.CrossRefPubMed
18.
Muratori C, Mangino G, Affabris E, Federico M. Astrocytes contacting HIV-1-infected macrophages increase the release of CCL2 in response to the HIV-1-dependent enhancement of membrane-associated TNFalpha in macrophages. Glia. 2010.
19.
•• Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8(1):33–44. This comprehensive review details cART era neuropathology in a manner that informs risk for neurodegeneration and provides a foundation for reversibility and treatment. CrossRefPubMed
20.
Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol. 2006;111(6):529–38.CrossRefPubMed
21.
Khanlou N, Moore DJ, Chana G, Cherner M, Lazzaretto D, Dawes S, et al. Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol. 2009;15(2):131–8.CrossRefPubMed
22.
Achim CL, Adame A, Dumaop W, Everall IP, Masliah E. Increased Accumulation of Intraneuronal Amyloid beta in HIV-Infected Patients. J Neuroimmune Pharmacol. 2009.
23.
Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology. 2009;73(23):1982–7.CrossRefPubMed
24.
Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P, et al. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: A case-control study. Neurology. 2010;75(2):111–5.CrossRefPubMed
25.
Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis. 2007;195(12):1774–8.CrossRefPubMed
26.
Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65–70.CrossRefPubMed
27.
Annamalai L, Bhaskar V, Pauley DR, Knight H, Williams K, Lentz M, et al. Impact of Short-Term Combined Antiretroviral Therapy on Brain Virus Burden in Simian Immunodeficiency Virus-Infected and CD8+ Lymphocyte-Depleted Rhesus Macaques. Am J Pathol. 2010.
28.
Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5):773–8.CrossRefPubMed
29.
Eden A, Price R, Hagberg L, Gisslen M. CSF Escape in uncommon in HIV-1-infected patients on stable ART. 17th Conference on Retroviruses and Opportunistic Infections, 2010. San Francisco, CA.
30.
Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog. 2009;5(4):e1000395.CrossRefPubMed
31.
Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56(3):416–23.CrossRefPubMed
32.
Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids. 2009;23(11):1359–66.CrossRefPubMed
33.
Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR, 3rd. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. Aids. 2009.
34.
Letendre S, McClemon D, Ellis R, Munoz-Moreno J, Way L, Franklin D, et al. Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment. 16th Conference on Retroviruses and Opportunistic Infections, 2009. Montreal, CA.
35.
McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543–55.CrossRefPubMed
36.
Alexaki A, Wigdahl B. HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog. 2008;4(12):e1000215.CrossRefPubMed
37.
Shiramizu B, Paul R, Williams A, Shikuma C, Watters M, Grove J, et al. HIV proviral DNA associated with decreased neuropsychological function. J Neuropsychiatry Clin Neurosci. 2007;19(2):157–63.PubMed
38.
Valcour VG, Shiramizu BT, Shikuma CM. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol. 2010.
39.
Hocquloux L, Avettand-Fenoel V, Jacquot S, Prazuck T, melard A, Viard J, et al. Abstract #515: Better HIV DNA depletion and CD4 restoration with HAART initiated at the time of primary HIV infection than with HAART started during chronic HIV infection. 16th Conference of Retroviruses and Opportunistic Infections, February 2009. Montreal, CA.’.
40.
Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A. 2005;102(43):15647–52.CrossRefPubMed
41.
Wang Y, Zhang J, Gutman B, Chan TF, Becker JT, Aizenstein HJ, et al. Multivariate tensor-based morphometry on surfaces: application to mapping ventricular abnormalities in HIV/AIDS. Neuroimage. 2010;49(3):2141–57.CrossRefPubMed
42.
Dewey J, Hana G, Russell T, Price J, McCaffrey D, Harezlak J, et al. Reliability and validity of MRI-based automated volumetry software relative to auto-assisted manual measurement of subcortical structures in HIV-infected patients from a multisite study. Neuroimage. 2010;51(4):1334–44.CrossRefPubMed
43.
Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, et al. White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol. 2009;15(2):187–95.CrossRefPubMed
44.
Stankoff B, Tourbah A, Suarez S, Turell E, Stievenart JL, Payan C, et al. Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology. 2001;56(1):112–5.PubMed
45.
Andersen AB, Law I, Krabbe KS, Bruunsgaard H, Ostrowski SR, Ullum H, et al. Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation. 2010;7:13.PubMed
46.
Ances BM, Sisti D, Vaida F, Liang CL, Leontiev O, Perthen JE, et al. Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology. 2009;73(9):702–8.CrossRefPubMed
47.
Ances BM, Vaida F, Yeh MJ, Liang CL, Buxton RB, Letendre S, et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis. 2010;201(3):336–40.CrossRefPubMed
48.
d’Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, et al. Cardio- and cerebrovascular events in HIV-infected persons. Aids. 2004;18(13):1811–7.CrossRefPubMed
49.
Blanco JJ, Garcia IS, Cerezo JG, de Rivera JM, Anaya PM, Raya PG, et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother. 2006;58(1):133–9.CrossRefPubMed
50.
Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214(2):231–41.CrossRefPubMed
51.
Becker JT, Kingsley L, Mullen J, Cohen B, Martin E, Miller EN, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73(16):1292–9.CrossRefPubMed
52.
Valcour V, Sacktor NC, Paul RH, Watters MR, Selnes OA, Shiramizu BT, et al. Insulin Resistance Is Associated With Cognition Among HIV-1-Infected Patients: The Hawaii Aging With HIV Cohort. J Acquir Immune Defic Syndr. 2006;43(4):405–10.CrossRefPubMed
53.
Bauer LO. Interactive effects of HIV/AIDS, body mass, and substance abuse on the frontal brain: A P300 study. Psychiatry Res. 2010.
54.
Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010.
55.
Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, Cherner M, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis. 2007;196(3):361–70.CrossRefPubMed
56.
Clifford DB, Smurzynski M, Park LS, Yeh TM, Zhao Y, Blair L, et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology. 2009;73(4):309–14.CrossRefPubMed
57.
Joska JA, Fincham DS, Stein DJ, Paul RH, Seedat S. Clinical correlates of HIV-associated neurocognitive disorders in South Africa. AIDS Behav. 2010;14(2):371–8.CrossRefPubMed
58.
Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74(16):1260–6.CrossRefPubMed
59.
Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, et al. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol. 2005;11(4):356–64.CrossRefPubMed
60.
Ances BM, Roc AC, Korczykowski M, Wolf RL, Kolson DL. Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients. J Neurovirol. 2008;14(5):418–24.CrossRefPubMed
61.
Rao VR, Sas AR, Eugenin EA, Siddappa NB, Bimonte-Nelson H, Berman JW, et al. HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci. 2008;28(40):10010–6.CrossRefPubMed
62.
Gupta JD, Satishchandra P, Gopukumar K, Wilkie F, Waldrop-Valverde D, Ellis R, et al. Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol. 2007;13(3):195–202.CrossRefPubMed
63.
Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K, Musisi S, et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis. 2009;49(5):780–6.CrossRefPubMed
64.
Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P. Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol. 2008;63(3):366–76.CrossRefPubMed
65.
Gandhi N, Saiyed Z, Thangavel S, Rodriguez J, Rao KV, Nair MP. Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses. 2009;25(7):691–9.CrossRefPubMed
66.
Samikkannu T, Saiyed ZM, Rao KV, Babu DK, Rodriguez JW, Papuashvili MN, et al. Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses. 2009;25(3):329–35.CrossRefPubMed
67.
Zhao Y, Navia BA, Marra CM, Singer EJ, Chang L, Berger J, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11(1):59–67.CrossRefPubMed
68.
Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. Aids. 2007;21(14):1877–86.CrossRefPubMed
69.
Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond). 2009;4(5):557–74.CrossRef
Metadata
Title
Pathogenesis of HIV in the Central Nervous System
Authors
Victor Valcour
Pasiri Sithinamsuwan
Scott Letendre
Beau Ances
Publication date
01-03-2011
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 1/2011
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-010-0070-4

Other articles of this Issue 1/2011

Current HIV/AIDS Reports 1/2011 Go to the issue

ReviewPaper

Coreceptors and HIV-1 Pathogenesis

ReviewPaper

Alterations of the B-Cell Response by HIV-1 Replication

ReviewPaper

Combination HIV Prevention: Significance, Challenges, and Opportunities

Erratum

Erratum to: Alterations of the B-Cell Response by HIV-1 Replication

ReviewPaper

HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies

ReviewPaper

Revisiting Immune Exhaustion During HIV Infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits